Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Novanta Inc filings on SEC EDGAR ↗
Novanta Inc. reported revenue of $305.0 million for the third quarter of 2026, up from $247.8 million in the prior year, though net income decreased to $2.0 million due to higher operating expenses and acquisition-related costs. The company significantly expanded its balance sheet through major business acquisitions, with total assets increasing from $1.8 billion to $3.2 billion during the first nine months of the year.
Novanta Inc. reported third quarter 2026 financial results with revenue increasing 23% year-over-year to $305 million, driven by 9.9% organic growth and the impact of the Riverpoint Medical acquisition. While GAAP net income decreased to $2 million due to acquisition-related costs, Adjusted EBITDA grew 38% to $80.3 million with a significant margin expansion of 290 basis points.
Term
Q3 2026
“The third quarter marked a significant milestone for Novanta as we closed the largest acquisition in our history and delivered strong financial results that exceeded our expectations.”
Matthijs Glastra, Chair and Chief Executive Officer
“Customer bookings increased 29%, reflecting strong commercial momentum and providing a solid foundation for future growth, expanding our backlog to $543 million.”
Matthijs Glastra, Chair and Chief Executive Officer
Novanta Inc. filed an amendment to its previous 8-K to provide required audited and pro forma financial statements following its acquisition of Runway Buyer, LLC. The transaction, which closed on July 23, 2026, involved Novanta's subsidiary acquiring all outstanding limited liability company interests of Runway Buyer from Runway Midco, LLC.